

EVIDENCE-BASED PLAN DESIGN DRUG LIST - AUGUST 2017

Disease State	Therapeutic Class	GPI	Excluded		
Hypertension	Beta Blockers	33			
	Calcium Channel Blockers (CCB)	34	34-00-00-22		
	ACE Inhibitors	36-10			
	Angiotensin II Receptor Antagonists (ARBs)	36-15			
	Direct Renin Inhibitors	36-17			
	Antiadrenergic Antihypertensives	36-20			
	Agents for Pheochromocytoma	36-30			
	Vasodilators	36-40			
	Antihypertensives - Misc	36-60			
	Diuretics / Diuretic Combinations	37			
	Antihypertensive Combinations	36-99	36-99-65	36-99-85	36-99-88
	Calcium channel blocker & HMG CoA reductase inhibit comb	40-99			
	Diabetes (drugs)	Insulins	27-10		
Amylin Analogs		27-15			
Incretin Mimetic Agents		27-17			
Sulfonylureas		27-20	27-23		
Biguanides		27-25			
Meglitinide Analogues		27-28			
Alpha-Glucosidase Inhibitors		27-50			
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors		27-55			
Dopamine Receptor Agonists - Antidiabetic		27-57			
Insulin Sensitizing Agents (TZDs)		27-60			
Sodium Glucose Co-Transporter 2 Inhibitors (SGLT2's)		27-70			
Combination products		27-99			